European equities opened Wednesday with cautious optimism, as investors weighed fresh diplomatic signals from U.S.-Iran negotiations against a wave of corporate earnings that delivered mixed results. The STOXX 600 index climbed 0.4% to 659.29 by 07:20 GMT, with mining shares leading the advance. Main Developments U.S. President Donald Trump reported “very good discussions” with Iran following all-day talks, fueling hopes that the five-month conflict could soon end and the blockaded Strait of Hormuz might reopen. That diplomatic backdrop provided a floor under risk appetite across the region. Read also: Pakistan's HugoBank gets Rs1.5bn SECP nod for digital launch Mining stocks were the standout performers, jumping 2.4% on the benchmark. Meanwhile, earnings took center stage, with diverging fortunes among major companies. Novo Nordisk raised its full-year profit and sales outlook, but the market punished the Danish drugmaker after a narrow miss on Wegovy pill sales and a trial setback for its next-generation obesity drug CagriSema. Shares dropped 3.5% as investors scrutinized the company’s ability to compete with Eli Lilly. Elsewhere, Sandoz jumped 7% after reporting a 9% rise in second-quarter net sales, while Siemens Energy gained 3.9% on record third-quarter results driven by AI data center demand and Middle East orders. Background The U.S.-Iran conflict has weighed on global markets for five months, with the Strait of Hormuz blockade disrupting energy shipments and heightening uncertainty. Diplomatic efforts have intensified recently, and any breakthrough would likely ease supply concerns and bolster investor sentiment. In the pharmaceutical sector, Novo Nordisk has been fighting to regain ground lost to Eli Lilly in the fast-growing obesity-drug market. The company’s recent turnaround efforts have been closely watched, with the Wegovy pill seen as a key growth driver for longer-term performance. Why It Matters A successful resolution of the Mideast talks could stabilize oil prices and restore normal shipping routes, benefiting global trade and European industries that rely on Gulf energy supplies. For equity investors, the outcome of these negotiations is a pivotal factor in determining whether the current market rally can be sustained. Corporate earnings also underscore the uneven recovery: while energy and generic drugmakers thrive, obesity-drug leaders face intense competitive pressure and clinical setbacks, highlighting the risks in high-growth sectors. What's Next Markets will closely monitor any formal announcements from the U.S.-Iran negotiations, as well as further corporate earnings reports for clues on sector momentum. Investors will also watch whether Novo Nordisk can address concerns about its obesity pipeline and regain confidence in its growth strategy.